CA2785643A1 - Highly permeating terbinafine formulation - Google Patents

Highly permeating terbinafine formulation Download PDF

Info

Publication number
CA2785643A1
CA2785643A1 CA2785643A CA2785643A CA2785643A1 CA 2785643 A1 CA2785643 A1 CA 2785643A1 CA 2785643 A CA2785643 A CA 2785643A CA 2785643 A CA2785643 A CA 2785643A CA 2785643 A1 CA2785643 A1 CA 2785643A1
Authority
CA
Canada
Prior art keywords
formulation
topical
terbinafine
topical formulation
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2785643A
Other languages
English (en)
French (fr)
Inventor
Servet Buyuktimkin
Nadir Buyuktimkin
Jagat Singh
John M. Newsam
Dominic King-Smith
Edward Kisak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvo Research Inc
Original Assignee
Nuvo Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Research Inc filed Critical Nuvo Research Inc
Publication of CA2785643A1 publication Critical patent/CA2785643A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2785643A 2009-12-23 2010-12-22 Highly permeating terbinafine formulation Abandoned CA2785643A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28996709P 2009-12-23 2009-12-23
US28996209P 2009-12-23 2009-12-23
US61/289,967 2009-12-23
US61/289,962 2009-12-23
PCT/US2010/061940 WO2011079234A2 (en) 2009-12-23 2010-12-22 Highly permeating terbinafine formulation

Publications (1)

Publication Number Publication Date
CA2785643A1 true CA2785643A1 (en) 2011-06-30

Family

ID=43770418

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2785643A Abandoned CA2785643A1 (en) 2009-12-23 2010-12-22 Highly permeating terbinafine formulation

Country Status (7)

Country Link
US (1) US9084754B2 (enExample)
EP (1) EP2544659A2 (enExample)
JP (1) JP5829217B2 (enExample)
CN (1) CN102770123A (enExample)
AU (1) AU2010336441B2 (enExample)
CA (1) CA2785643A1 (enExample)
WO (1) WO2011079234A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2672962T1 (sl) 2011-02-11 2015-06-30 Moberg Pharma Ab Nov protiglivni sestavek
WO2013093823A2 (en) * 2011-12-20 2013-06-27 Vyome Biosciences Pvt Ltd Topical oil composition for the treatment of fungal infections
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
NL2009669C2 (en) * 2012-10-19 2014-04-23 Dutch Renewable Energy B V Enhanced nail penetrating composition.
AU2013361106B2 (en) 2012-12-21 2017-06-01 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
WO2016061619A1 (en) 2014-10-21 2016-04-28 Hexima Limited A method of treatment
KR101690765B1 (ko) * 2015-04-17 2016-12-28 동아제약 주식회사 항진균성 활성물질을 포함하는 경피 제제
GB201511799D0 (en) * 2015-07-06 2015-08-19 Blueberry Therapeutics Ltd Composition and methods of treatment
EP3337471A4 (en) * 2015-08-17 2019-04-10 Ohio State Innovation Foundation METHOD AND COMPOSITIONS FOR IMPROVED TRANSITIONAL DELIVERY OF AR-12
JP6895429B2 (ja) * 2015-10-07 2021-06-30 エクソドス ライフ サイエンシーズ リミテッド パートナーシップ 局所抗真菌組成物
GB201605127D0 (en) * 2016-03-25 2016-05-11 Blueberry Therapeutics Ltd Composition and methods of treatment
WO2017216722A2 (en) * 2016-06-13 2017-12-21 Vyome Biosciences Pvt. Ltd. Synergistic antifungal compositions and methods thereof
BR112018075998A2 (pt) * 2016-06-13 2019-04-02 Vyome Therapeutics Limited. composições antifúngicas sinérgicas e métodos das mesmas
IL287622B (en) 2016-11-28 2022-07-01 Cellix Bio Private Ltd Compositions and methods for the treatment of fungal infections
WO2019214838A1 (en) * 2018-05-09 2019-11-14 Eviderm Institute Ab Use of an alcohol-containing composition for improving the skin barrier function
US20210154215A1 (en) * 2018-06-04 2021-05-27 Zenvision Pharma Llp Antifungal Cuticle Oil Composition
EP3603650A1 (fr) 2018-08-01 2020-02-05 Edix O Sarl Compositions injectables et a duree d'action prolongee pour leur utilisation dans le traitement de maladies de l'ongle et/ou pour accelerer la croissance de l'ongle
EP3829601B1 (fr) 2018-08-01 2024-05-29 Edix-O Sarl Compositions injectables à durée d'action prolongée pour leur utilisation dans le traitement de maladies de l'ongle
CN113208937A (zh) * 2020-01-21 2021-08-06 中国医学科学院北京协和医院 一种角质软化组合物及其制备方法和应用及治疗灰指甲的外用复方及其制备方法和应用
JP7664026B2 (ja) * 2020-08-06 2025-04-17 沢井製薬株式会社 エフィナコナゾール含有爪外用液
CN113234028B (zh) * 2021-04-29 2022-08-26 上海大学 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途
CN113786382B (zh) * 2021-11-04 2024-05-28 浙江得恩德制药股份有限公司 一种盐酸特比萘芬凝胶及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7713618L (sv) 1977-12-01 1979-06-02 Astra Laekemedel Ab Lokalanestetisk blandning
IT1180295B (it) 1984-10-08 1987-09-23 Durst Phototechnik Srl Ingranditore o riproduttore fotografico a colori
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US6841161B1 (en) 1997-05-14 2005-01-11 Galen (Chemicals) Limited Topical compositions
ATE269067T1 (de) * 1998-04-17 2004-07-15 Bertek Pharm Inc Topische formulierungen zur behandlung von nagel pilzerkrankungen
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
DE10035991A1 (de) * 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
KR100757611B1 (ko) 2001-09-04 2007-09-10 트롬스도르프 게엠베하 운트 코. 카게 알츠나이미텔 손발톱 성장의 기능장애와 질환을 치료하기 위한 플라스터
US20030091666A1 (en) * 2001-11-14 2003-05-15 Howard Murad Methods and compositions for treating dermatological disorders with Morinda citrifolia
US7138394B2 (en) 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
EP1635770B1 (en) 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antifungal nail coat and method of use
MXPA06002163A (es) 2003-08-25 2006-05-22 Foamix Ltd Espuma farmaceutica de penetracion.
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078599A1 (en) 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue
CA2500907A1 (en) 2005-03-15 2006-09-15 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
EP1858556A1 (en) 2005-03-16 2007-11-28 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
GB0511499D0 (en) * 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
US20070224261A1 (en) 2006-03-22 2007-09-27 Peter Draper Eutectic liquid drug formulation
MX2008015599A (es) * 2006-06-14 2009-03-06 Reddys Lab Ltd Dr Composiciones topicas.
WO2008121709A1 (en) * 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
WO2010010470A2 (en) 2008-07-23 2010-01-28 Tdt, Ltd Methods of administering topical antifungal formulations for the treatment of fungal infections
WO2011014850A2 (en) * 2009-07-31 2011-02-03 Nuvo Research Inc. Topical eutectic-based formulations

Also Published As

Publication number Publication date
JP2013515742A (ja) 2013-05-09
US20120309843A1 (en) 2012-12-06
EP2544659A2 (en) 2013-01-16
US9084754B2 (en) 2015-07-21
WO2011079234A3 (en) 2011-08-18
JP5829217B2 (ja) 2015-12-09
AU2010336441A1 (en) 2012-08-02
AU2010336441B2 (en) 2015-02-05
WO2011079234A2 (en) 2011-06-30
CN102770123A (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
AU2010336441B2 (en) Highly permeating terbinafine formulation for treating onychomycosis
WO2011014850A2 (en) Topical eutectic-based formulations
Zhai et al. Advances in lipid-based colloid systems as drug carrier for topic delivery
US20150342871A1 (en) Highly permeating terbinafine formulation
US20130338143A1 (en) Compositions for Transdermal Delivery of Active Agents
US20140004176A1 (en) Delivery of treatments transdermally for fungal infections and other indications
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
EP2498819A2 (en) Topical etoricoxib formulation comprsing an eutectic mixture of permeation enhancers
JP2016033168A (ja) Ｃｏｘ−２阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法
US20200383910A1 (en) Topical formulation
AU2019330022B2 (en) Novel topical formulation for intradermal application and uses thereof
ES2402921T3 (es) Composiciones químicamente estables de 4-hidroxi-tamoxifeno y sus aplicaciones terapéuticas
WO2011149645A1 (en) Topical etoricoxib formulation
US20160081915A1 (en) Transdermal formulations of fluticasone
WO2011041609A2 (en) Topical formulations
WO2021222453A1 (en) Fast-acting topical anesthetic formulations
ES2444398T3 (es) Composiciones farmacéuticas tópicas de ketoprofeno y metilsulfonilmetano
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
US12070440B2 (en) Topical formulations of nitroglycerin
CA3083274A1 (en) Systems and methods for topical creams for warming
EP4658241A1 (en) Compositions for topical administration
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法
CA3177346A1 (en) Fast-acting topical anesthetic formulations
JP2018145127A (ja) 皮膚貯留性改善剤及びこれを含む抗真菌外用製剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151002

FZDE Dead

Effective date: 20180612